Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
5位分析師的眼中，TScan藥物的專家展望
A clear picture of TScan Therapeutics's perception...Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
在過去的一季度裏，TScan Therapeutics (NASDAQ:TCRX) 的分析師評級從看好到看淡不一，由 5 位分析師提供。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表提供了他們最近的評級快照，展示了情緒在過去30天中的演變情況，並將其與之前的月份進行比較。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $12.6, along with a high estimate of $15.00 and a low estimate of $10.00. Highlighting a 1.18% decrease, the current average has fallen from the previous average price target of $12.75.
更深入的洞察由分析師制定的 12 個月價格目標，指示平均目標爲 $12.6，以及高估價 $15.00 和低估價 $10.00。當前平均價格已下降 1.18%，從之前的平均價格目標 $12.75 下降。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級：更深入的了解
A clear picture of TScan Therapeutics's perception...
通過對最近分析師...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間